Findings rationalize the use of anti-IL-10 antibodies to block migration of a class of T regulatory cells into the breast cancer microenvironment, thereby de-repressing the activity of antitumor T cells.
Specific recruitment of γδ regulatory T cells in human breast cancer
have all been identified in human cancers (15) (16) (17) (18) (19) . γδ T cells have been demonstrated to play a regulatory role in different forms of tolerance (20) (21) (22) (23) and have broad regulatory effects on CD4 + , CD8 + , IL-17 + and Treg cells in different diseases (24) (25) (26) (27) . Furthermore, studies from mouse tumor models have shown that γδ T cells in the tumor microenvironment may be involved in the induction of tumor-specific immune tolerance (28) (29) (30) . We previously observed that γδ1 Treg cells accumulated in breast cancer TILs have strong suppressive activities on responding T cells and block the maturation and activities of dendritic cells (19) . In order to explore the potential functions of γδ Treg cells in the immunopathogenesis of human breast cancer, we more recently demonstrated that high level of γδ T cells infiltrating in human breast cancer tissue was correlated with poor survival and high risk of relapse and could be used as a novel and independent prognostic factor in human breast cancer (31) .
Furthermore, those breast tumor-derived γδ Treg cells suppress innate and adaptive immunity through the induction of immunosenescence (32) . The involvement of human tumor immunity by this new subset of Treg cells was also reported by another group (33) . Thus, a better understanding of the suppressive mechanism(s) and regulations of tumor-derived γδ Treg cells is critical for the development of strong and innovative approaches to reverse the tumor suppressive microenvironment and improve effects of immunotherapy against breast cancer.
Dissecting mechanisms responsible for the accumulation of different types of Treg cells in tumor sites
will provide alternative strategies for anti-tumor immunotherapy. One potential mechanism is that the tumor microenvironment preferentially recruits Treg cells. It has been shown that the migration of Treg cells into tumor microenvironments may be facilitated by the expression of specific chemokines and their receptors (5, 34, 35) . Studies of Hodgkin's lymphoma and ovarian cancer showed that tumor microenvironmental CCL22 derived from cancer cells specifically recruits the CCR4 + CD4 + Treg cells to tumor sites (5, 36, 37) . In addition, CCR5-dependent chemotaxis is involved in Treg migration into pancreatic adenocarcinoma which expresses CCR5 ligand, CCL5 (35) . Although high percentages of γδ Treg cells exist in breast cancer TILs, the origin and mechanisms governing γδ Treg increase in cancer patients remains unknown.
In our efforts to explore the mechanisms responsible for the accumulation of γδ The purity of the T cells was >95%, as confirmed by flow cytometry. Human γδ1 Treg cells were established from the primary breast cancer tissues in our laboratory (19, 31, 32) . Breast tumor cell lines MCF-7 and MDA-MB-453 were obtained from the American Tissue Culture Collection (ATCC).
Melanoma MC135, MC586 and MC136 were established in our laboratory and maintained in RPMI 1640 medium containing 10% fetal calf serum (FCS). Melanoma 586mel and paired TIL586 were obtained from the Surgery Branch, NCI. Breast carcinoma cell lines (BC31, BC30, and BC20) were established in our laboratory and maintained in keratinocyte medium containing 25 mg/ml bovine pituitary extract, 5 ng/ml epidermal growth factor, and 2% heat-inactivated FBS, and penicillinstreptomycin (Invitrogen, Inc. San Diego, CA).
Generation of tissue-infiltrating lymphocytes
Tumor and normal tissue-infiltrating lymphocytes were generated from different tumor and normal tissues, as we previously described (19, 38, 39) . Briefly, tissues were minced into small pieces followed by digestion with collagenase type IV, hyaluronidase, and deoxyribonuclease. After digestion, cells were washed in RPMI1640, and then cultured in RPMI1640 containing 10% human AB serum supplemented with Lglutamine, 2-mercaptethanol and 50 U/ml of IL-2 for the generation of T cells.
Immunohistochemical and indirect immunofluorescence staining
The γδ T cells and IP-10 + tumor cells in cancer and normal tissues were determined using immunohistochemical staining, as we described previously (31) . The frozen sections were stained with a mouse anti-human γδ TCR (clone B1. 
Chemotaxis assay
Chemotaxis assays were performed using 24-well Transwell chemotaxis plates (5-μm pore size;
Corning Costar) as we described previously (19, 38) . 
Flow cytometry analysis
The expression markers on T cells and tumor cells were determined by FACS analyses after surface staining or intracellular staining with anti-human specific antibodies conjugated with either PE or FITC.
These human antibodies included: anti-IP-10, anti-CCR4, anti-CCR5, anti-CCR6, anti-CCR7, anti-CXCR3 and anti-TCRγδ, which were purchased from BD Biosciences or eBioscience. All stained cells were analyzed on a FACSCalibur flow cytometer (BD Bioscience) and data analyzed with FlowJo software (Tree Star).
Cytokine antibody array
Tumor cell lines (0.5 × 10 6 /ml) were cultured in 24-well plates for 48 hours, and chemokines and cytokines released into culture supernatants were determined using human Bio-Plex Chemokine Assay Kits (Bio-Rad) according to manufacturer's instructions. 
Statistical analysis
Unless indicated otherwise, data are expressed as mean ± standard deviation (SD). The significance of difference between groups was determined by paired or unpaired two-tailed Student's t-test or the one-way analysis of variance (ANOVA). Differences were considered significant for p values less than 0.05.
Results

High percentages of γδ Treg cells infiltrate in breast cancer tissues
To identify the suppressive mechanisms mediated by the breast cancer tumor microenvironment, we have demonstrated that γδ1 Treg cells were prevalent in breast tumor-infiltrating lymphocytes from breast cancer patients (19, 31, 32) . These breast tumor-derived γδ1 Treg cells not only suppress the proliferation and effects of naïve and tumor-specific T cells, but also inhibit the maturation and function of dendritic cells (19, 32) . However, the mechanism governing the γδ Treg cell accumulation in breast tumor sites remains unknown. To further investigate the role and regulation of γδ Treg cells in human breast cancer, we collected additional human breast cancer samples, generated TILs and characterized the tumor-infiltrating γδ1 T cells. Consistent with our previous results, we found that breast cancer-derived TILs contained high percentages of γδ1 T cells in the total TIL populations (4-77%, mean 29.1%), while in normal breast tissue-infiltrating lymphocytes and melanoma-derived TILs, the percentages of γδ T cells were low (2-4%, mean 2.8%; 3-8%, mean 5.8%, respectively) ( Fig. 1A ). These results prompted us to investigate whether γδ T cells were prevalent in situ in breast tumor sites (31) . We further performed immunohistochemical staining to detect γδ T cells in 46-freshly frozen breast cancer sections and patient-paired normal breast tissues (Fig. 1B) .
Significantly increased numbers of γδ T cells were detected in breast tumor tissues (43 of 46 tumor samples), but not in normal breast tissues (2 of 46 breast tissues). Notably, tumor nodes were surrounded by these γδ1 T cells. In addition, higher amounts of γδ1 T cells existed in cancer tissues from the late stage breast cancer patients (III and IV) than those from patients with early stages of cancer progression (I and II) (Fig. 1B) . These results combined with our previous studies clearly suggest the prevalence of γδ T cells in the breast tumor microenvironment which may play critical role in the immune pathogenesis of human breast cancer (31). 
Breast cancer cells attract the migration of γδ Treg cells
Given that high amounts of γδ1 Treg cells in breast tumor but not in normal breast tissues, we thus reasoned that human breast cancer cells may use the recruitment strategy to attract the migration of γδ1 Treg cells into tumor sites. To test this possibility, we first investigated if culture supernatants from freshly digested human tumor tissues, including melanoma, breast and colon cancers, can attract γδ1 Treg cell migration. As shown in Fig. 2A , we found that supernatants from breast cancer tissues induced significant migration of γδ Treg cells compared with culture medium in Transwell chemotaxis assays. In contrast, the supernatants from the culture supernatants of melanoma and colon cancer tissues had no or little chemotactic activity for γδ Treg cells. This result was further confirmed in the culture supernatants obtained from the primary tumor cell lines. We showed that supernatants from primary breast tumor cell lines, but not from melanoma and colon cancer cells dramatically induced γδ Treg cell chemotaxis (Fig. 2B) . These results indicate that breast cancer cells secrete molecules that selectively recruit γδ T cells to the tumor microenvironments.
Because estrogen receptor (ER) -negative breast cancer patients have a worse prognosis than ERpositive patients, we next determined whether ER expression status in breast cancer patients affects their capacity to attract the migration of γδ Treg cells into tumor sites. We found that the culture supernatants of digested breast tumor tissues collected from ER + and ER -breast cancer patients can both significantly attract the migration of γδ Treg cells to a similar level (Fig. 2C) , indicating that ER expression on breast cancer cells does not affect their ability to attract γδ Treg cells. Epidermal growth factor receptor 2 (HER2) expression level in tumor cells is another important prognostic factor for breast cancer outcomes. Our recent studies have further demonstrated a significant positively correlation between intra-tumoral γδ T cell numbers and HER2 expression in breast cancer patients (31) . However, we observed that culture supernatants from HER2 + and HER2 -human breast cancer tissues have a similar chemotactic activity on γδ Treg cells (Fig. 2D) . These data suggest ER or HER2 expression in breast cancers does not affect their chemotactic activity for γδ Treg cells. 
IP-10 secreted by breast tumor cells is responsible for the migration and trafficking of γδ Treg cells
To investigate which cytokines are secreted by breast cancer cell lines and involved in the specific recruitment of γδ1 Treg cells, we collected cell culture supernatants from breast cancer cell lines and determined the chemokines released into culture supernatants using a human chemokine antibody array. As shown in Fig. 3A , we found that primary breast tumor cell line BC31 secreted large amounts of IL-8, IP-10 and VEGF, and mid-level amounts of G-CSF, MCP-1 and RANTES, as well as some FGF and TGF-β, but not other cytokines and chemokines. We obtained very similar cytokine profiles from other breast tumor cell lines (data not shown). We further examined which cytokines/chemokines secreted by breast cancer cells are responsible for γδ Treg cell recruitment. We used specific neutralizing antibodies against the identified chemokines/cytokines and found that only IP-10 neutralizing antibody abolished the chemotactic activity of the breast cancer supernatant to attract γδ Treg cells (Fig. 3B) . In addition, we found that recombinant IP-10 had the same chemotactic activity for various γδ Treg cell lines, and the activity displayed a dose-dependent chemotaxis (Supplementary Fig. 1B) . These results suggest that breast cancer cells secrete IP-10 that recruits γδ T cells into the tumor microenvironment.
We next investigated whether IP-10 is the only functional chemokine that attracts the migration of γδ1
Treg cells by breast cancer cells. We first confirmed that breast cancer cell lines MCF7, MDA, BC30 and BC31, but not melanoma cell lines MC586 and MC136, highly expressed IP-10 using flow cytometry analyses with intracellular staining of IP-10 expression (Fig. 3C) (Fig. 3D) . We eliminated the function of IP-10 in the breast cancer cells using a neutralizing antibody and then tested whether IP-10-blocked breast cancer cells still had chemotactic activity for γδ Treg cells. We also included other types of T cells as controls, including γδ2 T, CD4 although these cells also expressed CXCR3 (Fig. 3E) . In addition, we found that breast tumor cells dramatically attracted Th17 cell migration, but neutralization of IP-10 cannot abolish the breast tumormediated chemotaxis of Th17 cells (Fig. 3E) . These results were consistent with our previous finding that breast tumor cells attracted human Th17 cells to tumor sites through RANTES and MCP-1, but not through IP-10 (38). These data may also suggest that tissue or cell type specificity is required for the interactions among chemokine/chemokine ligand-expressing cells (40) . showed that no significant difference of γδ Treg cell infiltration was found among human breast tumor tissues with different IP-10-expressing levels (Supplementary Fig. 2 ). infiltrating into breast tumor tissues from the groups injected with CD4 + and γδ2 T cells (Fig. 5B) .
Co-localization of γδ
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IP-10 controls γδ
Collectively, these results clearly indicate that human breast tumor cells can selectively attract γδ1
Treg cells into tumor sites in vivo.
We then determined if the human breast tumor-induced trafficking and migration of γδ Treg cells into the tumor sites is controlled by the tumor-derived IP-10 in vivo, using this adoptive transfer tumor model. γδ1 T cells were intravenously injected into MDA-MB-453-bearing NSG mice. Concurrently, mice were injected with human IP-10 neutralizing antibody into tumor sites before and after γδ1 Treg cell adoptive transfer, and the γδ1 T cell trafficking and accumulation into tumor sites were checked by the IVIS. As expected, treatment with neutralizing antibody against human IP-10, but not isotype control antibody, significantly blocked the trafficking and accumulation of γδ1 Treg cells into tumor sites (Fig. 6A) . Furthermore, we confirmed using the immunohistochemical staing of γδ T cells in tumor sections that high amount of γδ Treg cells infiltrated into breast tumor tissues obtained from isotype antibody treatment group, but not from the IP-10 neutralizing antibody treatment group (Fig. 6B ). These data further suggest that tumor-derived IP-10 is critical and controls the recruitment of γδ1 ability mediated by TIL586 CD8 + T cells (Fig. 6C) (3) (4) (5) . Importantly, the increased frequencies of Treg cells were clinically correlated with tumor pathogenesis (5, 8, 47, 48) . We have recently shown high percentages of γδ1 Treg cells with potent suppressive activity among TILs from breast cancer patients (19) . We further analyzed in situ the quantity of γδ1 T cells in tumor tissues with different cancer stages using immunohistochemical staining, and then performed retrospective and multivariate analyses of the correlations between γδ T cell levels with other prognostic factors and clinical outcomes (31) . We observed that γδ T cell numbers were significantly increased in breast cancer tissues but not in normal breast tissues, especially in the late stages (III and IV) of cancer patients (Fig. 1) . Furthermore, we found that patients with a high proportion of γδ T cells have advanced cancer stages, HER2 expression status (49, 50) . Given that our data have shown that breast cancer cells also secrete VEGF and TGFβ (Fig. 3A) , and no significant correlation between numbers of γδ Treg cell infiltration and IP-10 expression levels among human breast tumor tissues, as well as that we observed non-suppressive γδ1 T cells existing in the breast cancer TILs (19) , there still exists a possibility that conversion in situ may contribute to the accumulation of γδ Treg cells in the breast cancer tumor microenvironment. We will continue our efforts to explore other potential mechanisms responsible for the accumulation of γδ Terg cells in human breast cancer in the future studies. (Fig. 3 and (38) ). However, we observed that IP-10 secreted by breast cancer cells only selectively attracted the migration of γδ Treg cells, but not other CXR3-expressing T cell subsets. These studies may suggest that tissue or cell type specificity is required for the interactions among chemokine/chemokine ligand-expressing cells (40) . In support of this notion, our previous studies have shown that that breast cancer 
Treg cells into breast tumor sites in vivo.
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